Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

• Status: Completed
• Trial end date: 2020-12-08

Summary

The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, vorinostat and etoposide, is in treating cancer. The medication etoposide is a standard medication used in the treatment of cancer in children. Vorinostat is an experimental drug which targets a protein(s) that control the way cancer cells grow and divide. Vorinostat is approved by the FDA in adults with certain cancers but not approved yet in children.

There are two parts to this study. In the first part of this study, the phase I portion, a safe dose of the combination, vorinostat and etoposide. The goal of second part of this study, the phase II portion, is to see how effective the combination of vorinostat and etoposide is in treating cancer.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Alberta Children's Hospital; Arnold Palmer Hospital for Children; Children's Hospital Colorado; Children's Mercy Hospital & Clinics; Children's Mercy Hospital Kansas City; Dana-Farber Cancer Institute; Johns Hopkins All Children's Hospital; Johns Hopkins University; M.D. Anderson Cancer Center; Merck Sharp & Dohme Corp.; Milton S. Hershey Medical Center; Phoenix Children's Hospital; Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Florida
• Treatments: Etoposide; Etoposide phosphate; Vorinostat